We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+20.93%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$952M
AUM Growth
+$119M
Cap. Flow
-$4.06M
Cap. Flow %
-0.43%
Top 10 Hldgs %
45.23%
Holding
168
New
60
Increased
16
Reduced
31
Closed
41

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$23.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$16.8M
4
TVTX icon
Travere Therapeutics
TVTX
+$16.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$48M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.8M
3
MNKD icon
MannKind Corp
MNKD
+$19.8M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.36%
2 Miscellaneous 16.85%
3 Consumer Staples 1.74%
4 Technology 0.04%
5 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
126
Biogen
BIIB
$31.9B
– –
-40,000
Closed -$11.2M
CRIS icon
127
Curis
CRIS
$2.74M
– –
-175
Closed -$987K
CVS icon
128
CVS Health
CVS
$121B
– –
-89,330
Closed -$6.39M
DXCM icon
129
DexCom
DXCM
$32.6B
– –
-120,000
Closed -$1.06M
GERN icon
130
Geron
GERN
$842M
– –
-4,956
Closed -$22K
HOLX
131
CALL
DELISTED
Hologic
HOLX
– –
-25,000
Closed -$559K
LSTA icon
132
Lisata Therapeutics
LSTA
$13.9M
– –
-1,531
Closed -$1.57M
MDXG icon
133
MiMedx Group
MDXG
$689M
– –
-100,000
Closed -$874K
MNKD icon
134
MannKind Corp
MNKD
$1.14B
– –
-759,000
Closed -$19.8M
MYGN icon
135
PUT
Myriad Genetics
MYGN
$371M
– –
-10,000
Closed -$210K
SRPT icon
136
PUT
Sarepta Therapeutics
SRPT
$2.19B
– –
-650,000
Closed -$13.2M
UTHR icon
137
United Therapeutics
UTHR
$21.5B
– –
-7,000
Closed -$792K
ZBH icon
138
Zimmer Biomet
ZBH
$18.8B
– –
-20,600
Closed -$1.86M
CUTR
139
DELISTED
Cutera, Inc.
CUTR
– –
-22,400
Closed -$228K
INFI
140
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-350,000
Closed -$4.83M
DS
141
DELISTED
Drive Shack Inc.
DS
– –
-77,400
Closed -$402K
HRC
142
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-3,687
Closed -$152K
IMMU
143
DELISTED
Immunomedics Inc
IMMU
– –
-2,853
Closed -$13K
NAVB
144
PUT
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
– –
-5,000
Closed -$207K
ATHN
145
CALL
DELISTED
Athenahealth, Inc.
ATHN
– –
-2,500
Closed -$336K
ECYT
146
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-200,000
Closed -$2.14M
ECYT
147
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-200,000
Closed -$2.14M
ESRX
148
DELISTED
Express Scripts Holding Company
ESRX
– –
-2,080
Closed -$146K
ALOG
149
DELISTED
Analogic Corp
ALOG
– –
-1,644
Closed -$146K
AEGR
150
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-447,785
Closed -$31.8M
3 4 5
6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Perceptive Advisors held 168 positions worth $952M, up 14% from $833M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors's Q1 2014 filing shows 60 new, 16 increased, 31 reduced and 41 closed positions. Its largest new stake was Heron Therapeutics: 1,762,426 shares worth $24.5M. The largest sale was Celgene Corp, an estimated $48M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q1 2014 buy was Heron Therapeutics: 1,762,426 shares worth $24.5M.
  • Perceptive Advisors added most to Clovis Oncology, Inc. in Q1 2014, an estimated $10.4M increase.
  • Perceptive Advisors's biggest Q1 2014 reduction was Celgene Corp, cutting an estimated $48M.
  • Perceptive Advisors fully exited Aegerion Pharmaceuticals in Q1 2014, selling an estimated $31.8M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $952M portfolio in Q1 2014.
  • Perceptive Advisors opened 60 new positions and closed 41 in Q1 2014.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $952M.

Based on Perceptive Advisors's 13F filing for Q1 2014, filed 15 May 2014.